XML 50 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Jul. 31, 2023
Jan. 31, 2022
Aug. 31, 2018
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2018
Jun. 30, 2024
Jun. 30, 2023
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Other Commitments [Line Items]                        
Contractual obligation next 12 months       $ 50,000       $ 50,000        
Loss (gain) on strategic investment               0 $ 3,601      
Research and development       76,233 $ 58,771     135,912 127,915      
Restricted cash       5,770 $ 8,120     5,770 $ 8,120   $ 5,770 $ 5,770
Letter of Credit | Corporate Credit Card Program                        
Other Commitments [Line Items]                        
Restricted cash       2,000       2,000        
Letter of Credit | Fleet Program                        
Other Commitments [Line Items]                        
Restricted cash       400       400        
Stoke Therapeutics, Inc. [Member] | Research and Development [Member]                        
Other Commitments [Line Items]                        
Collaborative Arrangements Upfront Consideration And Transaction Payment   $ 60,000                    
Mile stone payments payable   907,500                    
Upfront consideration and transaction costs   $ 60,000                    
Collaboration agreement description   For the SYNGAP1 program, the two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits                    
License Agreements | North America                        
Other Commitments [Line Items]                        
Mile stone payments payable           $ 40,000            
License Agreements | Neuren | North America                        
Other Commitments [Line Items]                        
Upfront payment $ 100,000                      
Mile stone payments payable       50,000       50,000        
Upfront license fee     $ 10,000                  
Net sales               250,000        
Milestone payment as intangible asset           40,000            
PRV liability           $ 29,600            
License Agreements | Neuren | Research and Development [Member] | North America                        
Other Commitments [Line Items]                        
Upfront payment             $ 10,000     $ 100,000    
License Agreements | Neuren | Development Commercialization and Sales Milestones                        
Other Commitments [Line Items]                        
Upfront payment 831,300                      
Maximum                        
Other Commitments [Line Items]                        
Mile stone payments payable       $ 3,400,000       $ 3,400,000        
Maximum | License Agreements | Neuren | North America                        
Other Commitments [Line Items]                        
Mile stone payments payable $ 426,300   $ 455,000